Subacute sclerosing panencephalitis epidemiology and demographics
|
Subacute sclerosing panencephalitis Microchapters |
|
Differentiating Subacute sclerosing panencephalitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subacute sclerosing panencephalitis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subacute sclerosing panencephalitis epidemiology and demographics |
|
FDA on Subacute sclerosing panencephalitis epidemiology and demographics |
|
CDC on Subacute sclerosing panencephalitis epidemiology and demographics |
|
Subacute sclerosing panencephalitis epidemiology and demographics in the news |
|
Blogs on Subacute sclerosing panencephalitis epidemiology and demographics |
|
Directions to Hospitals Treating Subacute sclerosing panencephalitis |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
SSPE has been reported in all parts of the world, but in western countries it is considered a rare disease.
Fewer than 10 cases per year are reported in the United States, a dramatic decrease that followed the nationwide measles immunization program. However, in some countries like India, over 20 cases of SSPE per million people are reported each year.
SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself. 1 in 100,000 people infected with measles are at risk.